Hyperion Therapeutics Inc Watch

from 10-Q 91 pages Completion of Phase III Clinical Trial, Option and Mutual Release Agreement

from 10-K 24 pages Cic Severance Agreement

from 10-K 4 pages November 5, 2014 Bruce F. Scharschmidt

from 10-Q 12 pages General Release and Post-Separation Consulting Agreement

from 10-Q 49 pages Research and Licence Agreement by and Between: Yeda Research and Development Company Ltd.,

from 10-Q 95 pages Share Purchase Agreement by and Among Hyperion Therapeutics, Inc., Hyperion Therapeutics Israel Holding Corp. Ltd. Andromeda Biotech Ltd., and Clal Biotechnology Industries Ltd. April 23, 2014

from 10-K 3 pages First Amendment to Lease

from 10-K 9 pages Hyperion Therapeutics, Inc. 2012 Omnibus Incentive Plan Restricted Stock Unit Grant Notice

from 10-K 5 pages 2. Start Date. if You Choose to Accept This Offer, Your Employment With the Company Will Begin No Later Than June 24, 2013 Subject to the Contingencies and Requirements Set Forth in This Letter. You Should Not Take Any Significant Steps, Such as Relocating or Quitting Your Current Job, Until You Have Accepted This Offer by Returning to US a Signed Copy of This Letter, the Employee Confidential Information and Inventions Assignment Agreement, and the Consent to Conduct Background Investigation. 3. Compensation

from 10-K 5 pages 2. Start Date. if You Choose to Accept This Offer, Your Employment With the Company Will Begin No Later Than July 15, 2013 Subject to the Contingencies and Requirements Set Forth in This Letter. You Should Not Take Any Significant Steps, Such as Relocating or Quitting Your Current Job, Until You Have Accepted This Offer by Returning to US a Signed Copy of This Letter, the Employee Confidential Information and Inventions Assignment Agreement, and the Consent to Conduct Background Investigation. 3. Compensation. A. Base Salary. Your Starting Annual Base Salary Will Be Three Hundred Forty Six Thousand Dollars ($346,000.00), Payable in Accordance With the Company’s Normal Payroll Procedures. Your Salary Normally Will Be Reviewed Annually, and May Be Increased or Decreased in Connection With Any Such Review

from 10-Q 7 pages First Amendment to Distribution Services Agreement

from 8-K 54 pages Office Lease by and Between 2000 Sierra Point Parkway LLC, a Delaware Limited Liability Company, as Landlord and Hyperion Therapeutics, Inc., a Delaware Corporation as Tenant 2000 Sierra Point Parkway Brisbane, California 94065 October 14, 2013 Office Lease

from 8-K 29 pages Distribution Services Agreement

from 8-K 6 pages 601 Gateway Boulevard Second Amendment to Office Lease

from 10-Q 37 pages Hyperion Therapeutics, Inc. 2012 Omnibus Incentive Plan

from S-1/A 2 pages Agreement

from S-1/A 9 pages Settlement Agreement and First Amendment to License Agreement

from S-1/A 48 pages License Agreement

from S-1/A 108 pages Amended and Restated Collaboration Agreement by and Between Ucyclyd Pharma, Inc. and Hyperion Therapeutics, Inc. Dated March 22, 2012

from S-1/A 7 pages Hyperion Therapeutics, Inc. 2012 Omnibus Incentive Plan Non-Qualified Option Agreement